Corrigendum to "Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs" [Clin. Mass Spectrom. 14(Part A) (2019) 34-45]

J Mass Spectrom Adv Clin Lab. 2022 Aug 13:25:72. doi: 10.1016/j.jmsacl.2022.08.001. eCollection 2022 Aug.

¹ Unit of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
² Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
³ University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
⁴ University of Groningen, University Medical Center Groningen, Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.
⁵ University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands.
⁶ PRA Health Sciences Bioanalytical Laboratory, Assen, The Netherlands.
⁷ University of Groningen, University Medical Center Groningen, Department of Pharmacokinetics, Toxicology and Targeting, Groningen, The Netherlands.

Abstract

[This corrects the article DOI: 10.1016/j.clinms.2018.10.002.].